(VIANEWS) – SPBK1 ØSTFOLD AKE (SOAG.OL), NAVAMEDIC (NAVA.OL), KITRON (KIT.OL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. SPBK1 ØSTFOLD AKE (SOAG.OL)
36.1% sales growth and 11.66% return on equity
SpareBank 1 Østfold Akershus, a savings bank, provides various banking products and services in Østfold and the southern part of Akershus. The company offers savings, operating, tax deduction, deposit, placement, and currency accounts; and savings and investment products. It also provides consumer, construction, repayment, boat, motorcycle, and car loans; operating credit products; bank guarantees; liquidity loans with government guarantees; operating credit for agriculture; mortgage products; leasing and factoring services; and refinancing services. In addition, the company offers various insurance products, such as vehicle, house and travel, personal, animal, liability, work machine, interruption, condominium, cyber, truck, movable property, commercial building, project, transport, crime, bus, group life, health, leisure accident, occupational injury, accident insurance children, and sick pay insurance products; and pension products. Further, it provides credit, municipal payment, and other bank cards; payment terminal, debt collection, and document collection services; bonds, forwards, and currency options; accounting approved, invoice automatic, eGiro/Cremul, KID invoice, and OCR and eGiro payment services; and mobile and online banking services. The company was founded in 1835 and is headquartered in Moss, Norway.
Earnings Per Share
As for profitability, SPBK1 ØSTFOLD AKE has a trailing twelve months EPS of kr35.74.
PE Ratio
SPBK1 ØSTFOLD AKE has a trailing twelve months price to earnings ratio of 8.84. Meaning, the purchaser of the share is investing kr8.84 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.66%.
Growth Estimates Quarters
The company’s growth estimates for the current quarter and the next is 43.9% and 51.8%, respectively.
Yearly Top and Bottom Value
SPBK1 ØSTFOLD AKE’s stock is valued at kr316.00 at 22:20 EST, below its 52-week high of kr348.00 and way above its 52-week low of kr280.00.
Sales Growth
SPBK1 ØSTFOLD AKE’s sales growth is 29.2% for the current quarter and 36.1% for the next.
Moving Average
SPBK1 ØSTFOLD AKE’s value is above its 50-day moving average of kr315.68 and above its 200-day moving average of kr314.40.
More news about SPBK1 ØSTFOLD AKE.
2. NAVAMEDIC (NAVA.OL)
22.8% sales growth and 22.97% return on equity
Navamedic ASA, a pharmaceutical company, develops, produces, markets, and sells pharmaceuticals and related products in Northern Europe. The company's product portfolio includes prescription and non-prescription pharmaceuticals, as well as medical nutrition products, medical devices, food supplements, and cosmetics. It offers medical nutrition products for various therapeutic areas, including phenylketonuria, homocystinuria, maple syrup urine disease, tyrosinemia, methylmalonic acidemia/propionic acidemia, glutaric aciduria, isovaleric acidemia, and urea cycle disorders, as well as products for glycogen storage diseases and renal diseases, fat metabolism, malnutrition, and ketogenic diet. In addition, the company provides consumer health products consisting of non-prescription drugs and health care products for pain relief, cough and cold, gastro, obesity, women's health, and others primarily through pharmacies and drugstores; specialty pharmaceutical products in various therapeutic areas comprising dermatology, wound care, urology, and obesity; and branded generics, including cardiology products and antibiotics. It sells, markets, and distributes its products to hospitals, patients, and pharmacies. The company was formerly known as Glucomed AS and changed its name to Navamedic ASA in 2004. Navamedic ASA was incorporated in 2002 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, NAVAMEDIC has a trailing twelve months EPS of kr1.73.
PE Ratio
NAVAMEDIC has a trailing twelve months price to earnings ratio of 21.62. Meaning, the purchaser of the share is investing kr21.62 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 22.97%.
Volume
Today’s last reported volume for NAVAMEDIC is 20931 which is 23.9% below its average volume of 27506.
Revenue Growth
Year-on-year quarterly revenue growth grew by 93.3%, now sitting on 440.93M for the twelve trailing months.
Moving Average
NAVAMEDIC’s value is below its 50-day moving average of kr38.24 and higher than its 200-day moving average of kr36.31.
More news about NAVAMEDIC.
3. KITRON (KIT.OL)
16.8% sales growth and 29.51% return on equity
Kitron ASA operates as an electronics manufacturing services company in Norway, Sweden, rest of Europe, the United States, and internationally. It manufactures electronics that are embedded in the customers' products; and box-built electronic products. The company's services include development services, such as product development, product management, and re-engineering services; and industrialization services, including prototype manufacturing, evaluation of new products, component engineering and database, test development, design and build of high level assembly lines, and environmental durability testing. Its services also comprise sourcing and procurement services; manufacturing, assembling, and testing of electronic products for the professional market; redesign, repair, and maintenance; and logistics and distribution services. The company was incorporated in 1996 and is headquartered in Billingstad, Norway.
Earnings Per Share
As for profitability, KITRON has a trailing twelve months EPS of kr2.52.
PE Ratio
KITRON has a trailing twelve months price to earnings ratio of 15.04. Meaning, the purchaser of the share is investing kr15.04 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 29.51%.
More news about KITRON.
4. MEDISTIM (MEDI.OL)
16.7% sales growth and 31.89% return on equity
Medistim ASA develops, produces, services, leases, and distributes medical devices for cardio-vascular surgery in the United States, Europe, Asia, and internationally. It offers MiraQ Cardiac, a system that combines ultrasound imaging and transit time flow measurement (TTFM) in a single system for cardiac surgery; MiraQ Vascular, a system that combines ultrasound imaging and transit TTFM in a single system for vascular surgery; and imaging probes for intraoperative use. The company also provides various flow probes, such as QuickFit TTFM probes to accurately measure blood volume flow intraoperatively in various range of surgical applications; Vascular TTFM probes for enhancing surgical outcomes; and doppler probes that are used on the surface of the heart/vessel to search for intramural coronary arteries or to locate the position and quantify the degree of a stenosis. In addition, it distributes and sells third party medical equipment. The company was incorporated in 1984 and is headquartered in Oslo, Norway.
Earnings Per Share
As for profitability, MEDISTIM has a trailing twelve months EPS of kr6.31.
PE Ratio
MEDISTIM has a trailing twelve months price to earnings ratio of 40.89. Meaning, the purchaser of the share is investing kr40.89 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 31.89%.
More news about MEDISTIM.
5. MOWI (MOWI.OL)
14% sales growth and 24.25% return on equity
Mowi ASA, a seafood company, produces and supplies farmed salmon products worldwide. It operates through three segments: Feed, Farming, and Sales and Marketing. The company is involved in the salmon feed production, salmon farming and primary processing, and seafood secondary processing activities. It offers whole gutted fish, including Label Rouge and organic salmon; and white fish and other seafood products, as well as fillets, steaks, cutlets, portions, loins, kebabs, and steak combos. The company also provides value added products, such as breaded, pre-fried, dusted, marinated, grilled, battered, topped, filled with sauce, delicatessen, fresh fish ready meal, and smoked fish products. It offers its products under the Mowi, Mowi Salmon, Donegal Silver, Admiral's, Pieters, Laschinger, Kritsen, Ducktrap River, Harbour Salmon Co., Rebel Fish, Supreme Salmon, Olav's, Northern Harvest, and Mowi Nutrition brand names. The company was formerly known as Marine Harvest ASA and changed its name to Mowi ASA in December 2018. Mowi ASA was founded in 1964 and is headquartered in Bergen, Norway.
Earnings Per Share
As for profitability, MOWI has a trailing twelve months EPS of kr18.64.
PE Ratio
MOWI has a trailing twelve months price to earnings ratio of 9.65. Meaning, the purchaser of the share is investing kr9.65 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 24.25%.
Dividend Yield
As claimed by Morningstar, Inc., the next dividend payment is on May 19, 2023, the estimated forward annual dividend rate is 7.7 and the estimated forward annual dividend yield is 4.35%.
Volume
Today’s last reported volume for MOWI is 183434 which is 80.01% below its average volume of 917743.
Yearly Top and Bottom Value
MOWI’s stock is valued at kr179.80 at 22:20 EST, way under its 52-week high of kr230.30 and way higher than its 52-week low of kr130.15.
Sales Growth
MOWI’s sales growth is 4.9% for the current quarter and 14% for the next.
More news about MOWI.
6. TOMRA SYSTEMS (TOM.OL)
9.7% sales growth and 17.05% return on equity
Tomra Systems ASA provides sensor-based solutions for optimal resource productivity worldwide. It operates through three segments: TOMRA Collection, TOMRA Recycling, and TOMRA Food. The TOMRA Collection segment engages in the development, production, sale, and service of reverse vending machines and related data management systems. This segment is also involved in picking up, transporting, and processing empty beverage containers on behalf of beverage producers/fillers. The TOMRA Recycling segment engages in the development, production, sale, and service of sorting and processing technology for waste management companies or plant builders. This segment offers sorting systems for waste and metal material streams; and ore sorting systems for mining companies. The TOMRA Food segment is involved in the development, production, sale, and service of sorting and processing technology, including sensor-based sorting solutions and integrated post-harvest solutions to detect and eject unwanted materials from manufacturing and processing lines for fresh and processed food industries. The company was founded in 1972 and is headquartered in Asker, Norway.
Earnings Per Share
As for profitability, TOMRA SYSTEMS has a trailing twelve months EPS of kr3.79.
PE Ratio
TOMRA SYSTEMS has a trailing twelve months price to earnings ratio of 40.08. Meaning, the purchaser of the share is investing kr40.08 for every norwegian krone of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 17.05%.
Volume
Today’s last reported volume for TOMRA SYSTEMS is 515109 which is 61.87% above its average volume of 318222.
Yearly Top and Bottom Value
TOMRA SYSTEMS’s stock is valued at kr151.90 at 22:20 EST, way under its 52-week high of kr250.35 and above its 52-week low of kr151.00.
More news about TOMRA SYSTEMS.
7. MELEXIS (MELE.BR)
9.6% sales growth and 41.13% return on equity
Melexis NV designs, develops, tests, and markets advanced integrated semiconductor devices primarily for the automotive industry in Europe, the Middle-East, Africa, the Asia Pacific, and North and Latin America. The company provides magnetic position, latch and switch, current, inductive position, tire monitoring, temperature, optical, pressure, and speed sensor ICs. It also offers embedded motor driver, fan and pump, LED, and pre driver ICs; and LIN transceiver, CAN transceiver, RFID Transceiver NFC Sensor tag ICs. The company was founded in 1988 and is headquartered in Ieper, Belgium. Melexis NV is a subsidiary of Xtrion N.V.
Earnings Per Share
As for profitability, MELEXIS has a trailing twelve months EPS of €4.94.
PE Ratio
MELEXIS has a trailing twelve months price to earnings ratio of 18.81. Meaning, the purchaser of the share is investing €18.81 for every euro of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 41.13%.
Sales Growth
MELEXIS’s sales growth is 17.3% for the present quarter and 9.6% for the next.
Moving Average
MELEXIS’s value is higher than its 50-day moving average of €89.51 and above its 200-day moving average of €90.13.
Yearly Top and Bottom Value
MELEXIS’s stock is valued at €92.90 at 22:20 EST, way under its 52-week high of €106.90 and way above its 52-week low of €66.45.
Earnings Before Interest, Taxes, Depreciation, and Amortization
MELEXIS’s EBITDA is 57.88.
More news about MELEXIS.
